To build long-term credibility, domestic medical device enterprises must draw their fundamental confidence from independently controllable technological research and development. Founded in 2010, Hailais focuses on the segmented field of diabetes monitoring and takes technological innovation as its core driving force. As a national high-tech enterprise, it has long devoted itself to independent R&D, fostering core competitiveness exclusive to domestic brands.

From the early stage of its development, the brand adopted an independent R&D strategy. It has built professional R&D teams specializing in biosensing and electronic algorithms, set up independent research laboratories, and maintained continuous capital investment for testing and iteration of new technologies and new products. Rather than replicating ready-made external solutions, the company carries out targeted research addressing localized pain points in home-based blood glucose monitoring. Years of dedicated efforts have enabled the enterprise to accumulate a portfolio of independent intellectual property rights covering multiple functional modules including device structure, test strip reaction systems and data recording. Its proprietary technologies are continuously leveraged to improve product operational stability.

Contrary to the industry model that prioritizes marketing over R&D, Hailais translates technological achievements into practical products that balance testing stability and ease of operation, suitable for two major application scenarios: household use and primary care clinics. Meanwhile, the company has established high-standard supporting facilities for production and inspection. This enables standardized mass production based on self-developed technologies, ensures consistent performance across product batches, and prevents uneven quality control after technology commercialization.

Upholding the mission of leveraging technology to benefit people, the brand optimizes production costs through self-developed technologies and reasonably regulates end-user prices. This allows the general public to access compliant blood glucose monitoring devices built on proprietary technologies without excessive financial burden. Its nationwide service network also provides technical guidance to help users proficiently operate the equipment. Over more than a decade of commitment to independent innovation, Hailais has proven through sustained technological accumulation that local medical device manufacturers are fully capable of developing stable and reliable chronic disease monitoring products tailored to Chinese users relying on in-house R&D capabilities.